Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

6-1-2020

TFEB is a master regulator of tumor-associated macrophages in
breast cancer
Yong Li
University of South Carolina School of Medicine

Johnie Hodge
University of South Carolina School of Medicine

Qing Liu
University of South Carolina School of Medicine

Junfeng Wang
University of South Carolina School of Medicine

Yuzhen Wang
University of South Carolina School of Medicine

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Li, Yong; Hodge, Johnie; Liu, Qing; Wang, Junfeng; Wang, Yuzhen; Evans, Trent D; Altomare, Diego; Yao,
Yongzhong; Murphy, E. Angela; Razani, Babak; and Fan, Daping, "TFEB is a master regulator of tumorassociated macrophages in breast cancer." Journal for Immunotherapy of Cancer. 8, 1. e000543 (2020).
https://digitalcommons.wustl.edu/oa_4/112

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Yong Li, Johnie Hodge, Qing Liu, Junfeng Wang, Yuzhen Wang, Trent D Evans, Diego Altomare, Yongzhong
Yao, E. Angela Murphy, Babak Razani, and Daping Fan

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/112

Original research

TFEB is a master regulator of tumor-
associated macrophages in breast cancer
Yong Li,1 Johnie Hodge,1 Qing Liu,1 Junfeng Wang,1 Yuzhen Wang,1
Trent D Evans,2 Diego Altomare,3 Yongzhong Yao,4 E Angela Murphy,5
Babak Razani,2 Daping Fan   1

To cite: Li Y, Hodge J, Liu Q,
et al. TFEB is a master
regulator of tumor-associated
macrophages in breast cancer.
Journal for ImmunoTherapy
of Cancer 2020;8:e000543.
doi:10.1136/jitc-2020-000543
►► Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/jitc-
2020-000543).

YL and JH contributed equally.
Accepted 08 May 2020

© Author(s) (or their
employer(s)) 2020. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published by
BMJ.
For numbered affiliations see
end of article.
Correspondence to
Dr Daping Fan;
daping.fan@u scmed.sc.e du

Abstract
Background Tumor-associated macrophages (TAMs)
play key roles in the development of many malignant
solid tumors including breast cancer. They are educated
in the tumor microenvironment (TME) to promote tumor
growth, metastasis, and therapy resistance. However,
the phenotype of TAMs is elusive and how to regulate
them for therapeutic purpose remains unclear; therefore,
TAM-targeting therapies have not yet achieved clinical
success. The purposes of this study were to examine the
role of transcription factor EB (TFEB) in regulating TAM
gene expression and function and to determine if TFEB
activation can halt breast tumor development.
Methods Microarrays were used to analyze the gene
expression profile of macrophages (MΦs) in the context
of breast cancer and to examine the impact of TFEB
overexpression. Cell culture studies were performed to
define the mechanisms by which TFEB affects MΦ gene
expression and function. Mouse studies were carried out to
investigate the impact of MΦ TFEB deficiency or activation
on breast tumor growth. Human cancer genome data were
analyzed to reveal the prognostic value of TFEB and its
regulated genes.
Results TAM-mimic MΦs display a unique gene
expression profile, including significant reduction in TFEB
expression. TFEB overexpression favorably modulates TAM
gene expression through multiple signaling pathways.
Specifically, TFEB upregulates suppressor of cytokine
signaling 3 (SOCS3) and peroxisome proliferator-activated
receptor γ (PPARγ) expression and autophagy/lysosome
activities, inhibits NLRP3 (NLR Family Pyrin Domain
Containing 3) inflammasome and hypoxia-inducible
factor (HIF)-1α mediated hypoxia response, and thereby
suppresses an array of effector molecules in TAMs
including arginase 1, interleukin (IL)-10, IL-1β, IL-6 and
prostaglandin E2. MΦ-specific TFEB deficiency promotes,
while activation of TFEB using the natural disaccharide
trehalose halts, breast tumor development by modulating
TAMs. Analysis of human patient genome database reveals
that expression levels of TFEB, SOCS3 and PPARγ are
positive prognostic markers, while HIF-1α is a negative
prognostic marker of breast cancer.
Conclusions Our study identifies TFEB as a master
regulator of TAMs in breast cancer. TFEB controls TAM
gene expression and function through multiple autophagy/
lysosome-dependent and independent pathways.
Therefore, pharmacological activation of TFEB would be a
promising therapeutic approach to improve the efficacy of
existing treatment including immune therapies for breast

cancer by favorably modulating TAM function and the
TME.

Background
Tumor-associated macrophages (TAMs) play
key roles in the development of many malignant solid tumors including breast cancer.1
They are educated in the tumor microenvironment (TME) to aid in tumor growth,
metastasis, and therapy resistance.2 TAMs
have been considered M2-like macrophages
(MΦs); but they are much more complex
than M2 MΦs that are typically induced by
interleukin (IL)-4/IL-13 signaling. Many
signaling pathways in TAMs are triggered by
factors within the TME. A broad arsenal of
molecules is subsequently produced by TAMs
and executes tumor-promoting functions.3
During the initiation and development
of breast cancer, tumor cells secrete soluble
mediators such as colony stimulating factor
1 (CSF1), C-
C motif chemokine ligand 2
(CCL2), IL-10, and transforming growth
factor β1 (TGFβ1), and create a hypoxic
and nutrient-
depleted milieu.4 CSF1 and
CCL2 recruit monocytes/macrophages from
circulation and promote proliferation of
the recruited and mammary tissue resident
MΦs.5 Factors such as IL-10 and TGFβ1 from
cancer cells and tumor stromal cells induce
TAMs to secrete molecules such as arginase
1 (Arg1), IL-10, and TGFβ1, forming paracrine and autocrine loops. Arg1 depletes arginine in the TME, which is essential for T cell
proliferation.6 IL-10 directly suppresses T cell
function,7 while TGFβ1 exerts immunosuppression, promotes cancer cell proliferation,
and induces epithelial to mesenchymal transition and cancer stem cell generation.8
Cytokines such as IL-1β and IL-6, as well
as various Toll-
like receptor ligands generated within the TME, act on TAMs to induce
them to secrete more inflammatory cytokines
and growth factors, creating an unresolving
chronic inflammatory milieu.9 10 The chronic
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low-
grade inflammation results in immune exhaustion
and cancer stem cell generation.9 Hypoxia in the TME
activates hypoxia-induciblefactor 1α (HIF-1α), which triggers a hypoxia signaling cascade, leading to the production of pro-angiogenic factors such as vascular endothelial
growth factor (VEGF).11 HIF-1α signaling also alters lipid
metabolism pathways leading to production of PGE2,
which is known to cause immunosuppression, angiogenesis, and lymphangiogenesis in breast tumors.12 13
Autophagy plays various roles in tumors. On the one
hand, cancer cell autophagy may render cancer cells
apoptosis resistant.14 On the other hand, autophagy
and lysosomal activity in MΦs may lead to attenuation of
inflammation by counteracting the NLRP3 (NLR Family
PyrinDomain Containing 3) inflammasome.15 Autophagy
also may lead to degradation of HIF-1α, de-escalating the
hypoxia signaling cascade.16
Because TAMs are equipped with a wide range of pro-
tumor effector molecules, and MΦs are the first line of
defense against infection, TAM-
targeting cancer treatment strategies via depleting MΦs or inhibiting a single
type of molecule are either harmful or insufficient.
Targeting TAMs at a critical point to keep multiple pro-
tumor pathways in check would be more desirable. Therefore, the identification of such a nexus in TAM biology
is essential for the future success of TAM-targeting antitumor approaches.
Transcription factor EB (TFEB) controls the expression of genes involved in autophagy and lysosome biogenesis in response to various stimuli.17 Under cellular stress
conditions, TFEB is translocated from the cytoplasm to
the nucleus, and binds to the promoter of the target
genes in the Coordinated Lysosomal Enhancement and
Regulation (CLEAR) network which are involved in
vesicle formation, cargo recognition, lysosome fusion
and cargo degradation.18 Due to its role in the stress
responses, enhancement of TFEB activity has emerged as
a potential therapeutic approach for multiple lysosomal
and protein aggregation disorders, including atherosclerosis and neurodegenerative diseases.19–21
However, the functions of TFEB are not limited to
autophagy and lysosome biogenesis. TFEB is activated
in MΦs during bacterial infection or stimulation with
bacterial components, suggesting TFEB might perform
evolutionarily conserved defense functions in the innate
immune system.22 Recently, our laboratory discovered an
important role of TFEB in macrophage (MΦ) education
in breast cancer.23 We showed that TFEB is inactivated
and downregulated in TAMs by breast cancer cell-derived
TGFβ1, leading to an M2-
like polarization via signal
transducer and activator of transcription 3 (STAT3) activation, independent of the autophagy-
lysosome axis.23
In this current study, we aim to further examine how
deficiency and overexpression of TFEB affects MΦ gene
expression and functions in the context of breast cancer,
and to explore if activation of MΦ TFEB by trehalose, a
natural sugar, may serve as a novel therapeutic approach
for breast cancer.
2

Materials and methods
Animals
BALB/c and C57BL/6 mice (female, 6–8 weeks old)
were purchased from Jackson Laboratories (Bar Harbor,
Maine, USA). A TFEBflox mouse line was generated using
the ES cells from EUCOMM depository in Europe, which
are the same cells used for generation of liver-specific
TFEB knockout mice.24 LysM-Cre mice were purchased
from Jackson Laboratories and crossed with TFEBflox mice
to generate MΦ-specific TFEB knockout (MΦ-TFEB-/-)
mice. MΦ-specific TFEB transgenic (MΦ-TFEBtg) mice
were generated and characterized previously.25 Female
FVB/N mice were bred with male heterozygous C3(1)/
SV40Tag mice (a gift from Dr Jeffrey Green, National
Cancer Institute). All mice were housed in the University
of South Carolina or Washington University in St. Louis
Animal Research Facilities.
Cell culture
The 4T1 mouse mammary tumor cell line was obtained
from the American Type Culture Collection (ATCC).
EO771 cells were maintained in culture as described
previously.23 Peritoneal MΦs (pMΦs) were isolated from
thioglycollate-elicited mice. Bone marrow cells from age-
matched female wild-
type (WT) C57Bl/6, MΦ-TFEBtg
and MΦ-TFEB-/- mice were used to generate bone
marrow–derived MΦs (BMDMs). Bone marrow cells were
seeded in 6-well or 12-well plates for 4 hours, and non-
adherent cells were removed, then cultured in complete
medium containing 30% L929 cell-conditioned medium
as a source of M-CSF for 7 days. The cells were cultured
in high glucose Dulbecco’s modified Eagle medium
(DMEM; Invitrogen Life Technologies) with 10% fetal
bovine serum (FBS) (Invitrogen) and penicillin/streptomycin at 37°C in a humidified 5% CO2 atmosphere. MΦs
were polarized according to established protocols.26
Tumor conditioned medium
Tumor conditioned medium (TCM) was prepared by
culturing 4T1 or EO771 cells following the procedures
described previously.23 Briefly, tumor cells were seeded at
5×106 cells per 75 cm2 dish and cultured to 90% confluence. Then, the medium was removed, and the cells
were rinsed with serum-free DMEM twice. The medium
was then replaced with fresh serum-free DMEM, and the
supernatant was collected after 24 hours. The collected
TCM was centrifuged to remove cells and filtered through
a 0.45 µm filter (Corning).
Microarray
BMDMs from MΦ-TFEBtg and WT mice were treated
with either serum-free DMEM (control), or serum-free
DMEM supplemented with 20% concentrated EO771
TCM (ECM) for 24 hours. Cells were then rinsed twice
with phosphate-
buffered saline (PBS) and lysed using
700 µL Qiazol. RNA was extracted using the miRNeasy
kit (Qiagen). Samples were then further cleaned prior to
analysis using the RNeasy MinElute Cleanup Kit (Qiagen)
Li Y, et al. J Immunother Cancer 2020;8:e000543. doi:10.1136/jitc-2020-000543
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protocol. An Agilent 2100 Bioanalyzer was used to determine both the quality and the quantity of the RNA
samples. All samples had an RNA integrity number of
>8. RNA amplification and labeling was performed using
the Agilent Low Input Quick Amp labeling kit according
to the manufacturer’s instructions. RNA was again purified using the Qiagen RNeasy mini kit. Dye incorporation and cRNA yield were also assessed. After labeling,
samples were hybridized to SurePrint G3 Mouse GE
8×60K Microarrays (Cat. # G4858A-028005) using a gene
expression hybridization kit (Agilent) according to the
manufacturer’s instructions. A high-
resolution Agilent
DNA microarray scanner (Cat. # G2565CA) was used to
obtain the raw data and images were saved in TIFF format
for subsequent microarray analysis. Data were extracted
from these images and background corrected data were
uploaded into GeneSpring GX software for analysis.
After quantile normalization of the data, differentially
expressed genes were identified by using the moderated
t-test with Benjamini-Hochberg multiple testing correction. Cut-off values of 0.05 and 2.0 were used for p-value
and fold-change, respectively. Unsupervised hierarchical
cluster analysis was performed with GeneSpring GX. Gene
ontology (GO) analysis was performed with GeneSpring.
Ingenuity Pathway Analysis (Qiagen) was performed on
these data in order to further investigate the interconnection between differentially expressed genes and their
biology. A heatmap was generated using normalized
intensities and colored to represent gene expression variations for each individual gene.
In vivo cancer models
For the tumor growth experiments, female BALB/c
or C57BL/6 mice 6–8 weeks old, 4T1 or EO771 cells
(2×105) in 20 µL PBS were injected subcutaneously
into the mammary fat pads immediately caudal to
the fourth pair of nipples. Tumor volume was determined by caliper measurement and using the equation
volume=(length×width2)/2.
Cell isolation
Tumors were weighed, cut into small fragments (<3 mm)
and digested in 5 mL of dissociation solution (RPMI 1640
medium supplemented with 10% FBS, Collagenase type
I (200 U/mL), and DNase I (100 µg/mL)) for 60 min at
37°C. Erythrocytes were lysed with red blood cell lysing
buffer (Sigma, St. Louis, Missouri, USA). Cell suspensions
were passed through 70 µm cell strainers, then washed
and resuspended in staining buffer. TAMs (F4/80+) were
isolated from tumor suspensions using EasySep PE or
FITC Positive Selection Kits (Stem Cell Technologies).
Flow cytometry
Cell populations in the tumors were analyzed using ﬂow
cytometry as previously described.23 Brieﬂy, cells were
stained with anti-CD3 FITC, anti-CD4 APC or anti-CD8
APC, and anti-CD25 PE (Biolegend) in PBS containing
2% FBS for 30 min at 4°C. Samples were washed twice with
Li Y, et al. J Immunother Cancer 2020;8:e000543. doi:10.1136/jitc-2020-000543

staining buffer and analyzed with ﬂow cytometry using a
BD FACS Aria II ﬂow cytometer and CXP software V.2.2.
Data were collected for 20,000 live events per sample.
Luciferase reporter assay
To identify TFEB binding sites in the PPARγ promoter, we
searched for the E-box motifs on peroxisomeproliferator-
activated receptor γ (PPARγ) promoter or intron regions
and found four E-boxes in the upstream region of mouse
TFEB transcription start site. The promoter region
containing TFEB binding sites were cloned into pGL3
basic vector to generate three constructs: PPARγ-1158
(−797 to +361) contains all 4 E-boxes; PPARγ-891 (−530
to +361) contains E boxes 2–4 which are close to each
other; and PPARγ-464 (−103 to +361) does not contain
any E-boxes. RAW264.7 cells were seeded in triplicate
in 12-well plates and allowed to settle for 12 hours, then
transfected with one of the above pGL3-PPARγ promoter
plasmids or empty pGL3 plasmids and pRL-CMV (internal
control) as well as either lentiviral TFEB (PWPI-TFEB) or
control lentiviral vector (PWPI). The luciferase of both
firefly and Renilla signals were measured using Dual Luciferase Reporter assay kits (Promega, Madison, Wisconsin,
USA). Luciferase activity was normalized to Renilla activity
to control for transfection efficiency. The level of luciferase activity of the empty vector and in the absence of
TFEB (PWPI) was defined as ‘1’. Fold activation was estimated according to this level of activity.
Quantitative real-time PCR
Total RNA was isolated and purified using Qiagen RNeasy
Kits (Qiagen). RNA (2 µg) was then reverse-transcribed
using iScript cDNA Synthesis Kit (Bio-Rad). Quantitative
real-time PCR (qPCR) was conducted on a CFX96 system
(Bio-
Rad) using iQ SYBR Green Supermix (Bio-
Rad).
All primers used for qPCR analysis were synthesized by
Integrated DNA Technologies. All assays were conducted
following the manufacturer’s instructions. The relative amount of target mRNA was determined using the
comparative threshold (Ct) method by normalizing
target mRNA Ct values to those of 18S RNA. PCR thermal
cycling conditions were 3 min at 95°C, and 40 cycles of
15 s at 95°C and 58 s at 60°C. Samples were run in triplicate. The primer sequences are listed in online supplementary table S1.
Western blot analysis
Whole cell lysate was prepared using RIPA buffer (Pierce)
supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktail (Sigma). The protein concentrations were determined using the BCA protein assay
kit (Pierce, Rockford, Illinois, USA). Samples were
diluted in 2×Laemmli buffer (Bio-Rad) and boiled for
10 min. Proteins (20 µg) were separated in 10% SDS-
polyacrylamide gel electrophoresis precast gels (Bio-
Rad) and transferred onto nitrocellulose membranes
(Bio-Rad). Non-specific binding sites on the membranes
were blocked with 5% non-fat milk in phosphate buffered
3
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saline with tween 20 (PBST). Membranes were first
probed with TFEB (1:2000; Bethyl Laboratories), PPARγ
(1:1000), NLRP3, p-p65, p65, Lamp1, Hif1α, MIF, cytosolic phospholipases A2 (cPLA2), inducible nitric oxide
synthase (iNOS), arginase 1 (Arg1), or β-actin (1:1000;
Sigma) antibodies, followed by goat anti-rabbit or anti-
mouse secondary antibody conjugated with horseradish
peroxidase (Millipore). Protein detection was conducted
using Pierce ECL Substrate (Pierce).
Transcriptomic data retrieval and survival analysis
The breast cancer patient survival data were obtained
from The Cancer Genome Atlas (TCGA) database and
Kaplan-Meier plotter database (www.kmplot.com).27
Based on the best expression cut-off value (FPKM) of
each gene, patients were classified into two groups, association between survival rate and gene expression was
examined, or the HR was calculated. Survival curves were
estimated with the Kaplan-Meier method and compared
using the log-rank test.
Immunofluorescence staining
For breast tumor tissues from patients, deidentified
formalin-fixed paraffin embedded tissues were collected
from mastectomy surgery with ethical approval by Nanjing
Drum Tower Hospital in 2015. Sections were cut (4 µm
thick), transferred to a warm water bath, and placed on
a glass slide. The following immunofluorescence staining
test was examined by the corresponding anti-
human
antibodies: TFEB (1:300, Invitrogen) and CD68 (1:300,
Abcam).
Statistical analysis
Data were presented as mean±SD or SEM as indicated.
Statistical significance was calculated using the Student’s
t-test (two group comparison) or one-way analysis of variance (ANOVA) followed by post hoc Dunnett’s test (multigroup comparison) using the GraphPad Prism V.6.0. For
the TCGA database analysis, p values were calculated
for the comparison of the 5-year survival rates between
the two groups. For the Kaplan-Meier plotter database,
univariate Cox proportional hazard modeling of the
genes was used to determine their independent impact
on patients’ survival, and to estimate the corresponding
HR, setting low expression as the reference group; HRs
and 95% CI, as well as the p values, were reported. P<0.05
was considered significant.

Results
Breast cancer cell conditioned medium treatment results in a
unique gene expression profile in MΦs
TAMs are often considered to adopt an M2 phenotype,
which is typically induced by IL-4 or IL-13. However, the
TME is a complex milieu; in addition to IL-4 and IL-13,
many other factors, including hypoxia, apoptotic cancer
cells and their debris, growth factors, and proinflammatory or anti-inflammatory cytokines secreted from cancer
4

cells and stromal cells, act on TAMs. Therefore, the phenotype of TAMs is much more complex than that of typical
M2 MΦs. Breast cancer EO771 cell conditioned medium
(ECM) was used to treat BMDMs to mimic TAMs, and a
microarray was performed to compare the gene expression profiles between those TAM-mimic cells and control
MΦs. The results are summarized in a heatmap; we also
plot a heatmap to compare the expression of the same set
of genes in control MΦs, M1 MΦs (induced by LPS+IFNγ),
and M2 MΦs (induced by IL-4) using the data we obtained
from a previous microarray,28 in order to visualize the
gene expression differences between TAM-
mimic cells
and M1 or M2 MΦs (figure 1A). First, we confirmed that
like in IL-4 induced M2 MΦs, some typical M2 markers,
including Arg1, IL-10, and TGFβ1, are increased in ECM-
treated MΦs. However, unlike in M2 MΦs, the expression
of many M1 markers, such as IL-1β, IL-6, tumor necrosis
factor α (TNFα), iNOS and NLRP3, also are significantly
increased in ECM-treated MΦs. Additionally, more resembling M1 than M2 MΦs, ECM-treated MΦs have elevated
expression of HIF-1α, macrophage migration inhibitory
factor (MIF), cPLA2, and cyclo-
oxygenase-2 (COX2).
COX2 catalyzes the production of prostaglandin E2
(PGE2), a key tumor-promoting and immune-suppressive
metabolite in the TME. Also, unlike M2 MΦs but more
like M1 MΦs, ECM-treated MΦs have reduced expression
of TFEB and PPARγ. PPARγ controls several inflammatory response and cellular metabolism pathways. Using
western blot analysis, we confirmed that TFEB and PPARγ
are increased in M2 MΦs, but reduced in ECM-treated
MΦs; while NLRP3 is reduced in M2 MΦs, but increased
in ECM-treated MΦs (figure 1B).
MΦ TFEB ablation promotes breast tumor growth
We previously showed that TFEB overexpression in MΦs
attenuated orthotopic breast tumor growth, while injection of MΦs with lentiviral knockdown of TFEB accelerated breast tumor growth.23 To further examine the
function of MΦ TFEB in breast tumors, we aimed to test if
TFEB ablation in MΦs promotes breast tumor growth via
conferring TAMs with a more tumor-promoting phenotype. We therefore generated MΦ-specific TFEB knockout
(MΦ-TFEB-/-) mice (figure 1C), whose BMDMs express
TFEB at only ~25% level of WT control (figure 1D,E).
We generated bone marrow chimeric mice by transplanting bone marrow cells from MΦ-TFEB-/- mice or
Cre-littermates to lethally irradiated WT C57Bl/6 mice
using our standard protocol.23 We implanted EO771 cells
into mammary fat pads of the mice 4 weeks after the bone
marrow transplantation. Tumor growth was monitored for
35 days, showing TFEB ablation in MΦs promoted tumor
growth (figure 1F). At sacrifice, the weight of tumors
from mice transplanted with bone marrow cells from
MΦ-TFEB-/- mice was significantly increased compared
with that of control mice (figure 1G). Single cell suspensions were obtained from tumors, and flow cytometry
analysis showed that tumors in MΦ-TFEB-/- bone marrow
recipient mice contained similar percentages of total
Li Y, et al. J Immunother Cancer 2020;8:e000543. doi:10.1136/jitc-2020-000543
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Figure 1 Downregulation of TFEB renders macrophages (MΦs) tumor-promoting. (A) Clustering of gene expression profiles
of individual runs for all common genes upregulated or downregulated by IL-4, LPS+IFNγ, or EO771 cell conditioned medium
(ECM) are depicted as heatmap matrices according to the color scale shown at the bottom. Each group has four or three
biological replicates. The microarray data have been deposited in Gene Expression Omnibus (GEO) database (accession
numbers GSE73311 and GSE139554). (B) Western blot analysis of TFEB, PPARγ, and NLRP3 proteins in mouse peritoneal
MΦs treated with or without 4T1 or ECM for 24 hours, and in IL-4 induced M2 MΦs with a comparison to non-treated M0 cells.
(C) The strategy to generate MΦ-specific TFEB knockout mice. A map of the TFEB locus shows the location of LoxP sites and
deletion of Exons 4–5 on exposure to LysM-Cre. (D–E) Quantitative real-time PCR (qPCR)(D) and Western blot (E) of peritoneal
MΦs derived from control (TFEBfl/fl) and MΦ-TFEB-KO mice. Ponceau stain of total protein is shown as loading control. In
qPCR data, data are shown as mean±SEM, n=3, **p<0.01, two-tailed Student’s t-test. (F) Tumor growth curve in C57Bl/6
mice transplanted with bone marrow cells from TFEBfl/fl (BM-WT) or MΦ-TFEB-KO (BM-TFEB-/-) mice, with representative
tumors shown as inserts. (G) Mice were sacrificed, and the tumor weight of each mouse was measured on day 35 after tumor
cell inoculation. (H) Flow cytometry analysis of MΦs in the cells isolated from the resected orthotopic breast tumors. (I) Gene
expression in MΦs isolated from the breast tumors was analyzed by qPCR. Data are shown as mean±SEM, n=3, *p<0.05,
**p<0.01, ***p<0.001; two-tailed Student’s t-test. Arg1, arginase 1; COX2, cyclo-oxygenase-2; cPLA2, cytosolic phospholipases
A2; HIF-1α, hypoxia-inducible factor 1α; IL, interleukin; NLRP3, NLR Family Pyrin Domain Containing 3; PPARγ, peroxisome
proliferator-activated receptor γ; TFEB, transcription factor EB; TNFα, necrosis tumor factor α; VEGFA, vascular endothelial
growth factor A; WT, wild type.
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F4/80+ MΦs or CD3+ T cells, but more CD206+ MΦs and
CD3+/CD4+ T lymphocytes (figure 1H and online supplementary figure S1). MΦs were isolated from the tumors,
and gene expression was analyzed using qPCR. The result
shows that TAMs from the tumors in MΦ-TFEB-/- bone
marrow recipient mice had lower expression levels of
TFEB (~50%) and PPARγ (~70%), but higher levels of
Arg1 (~3.7-fold), IL-10 (~2.2-fold), and COX2 (~2.5-fold)
(figure 1I), suggesting TFEB ablation exaggerated the
tumor-promoting phenotype of TAMs in breast tumors.
TFEB overexpression modifies MΦ gene expression in
response to TCM treatment
With the eventual goal of developing strategies to increase
TFEB expression or activate TFEB in TAMs to halt breast
tumor development, we next examined how TFEB overexpression may ameliorate the aberrant gene expression
profile in TAMs. We have generated MΦ-TFEBtg mice in
our previous studies.21 23 BMDMs from WT or MΦ-TFEBtg
mice were treated with ECM and a microarray analysis
was performed. A heatmap shows that 148 genes were
downregulated, and 140 genes were upregulated in ECM-
treated TFEBtg MΦs compared with ECM-
treated WT
MΦs (online supplementary figure S2A). Most significantly affected pathways relevant to MΦ functioning
in inflammation and cancer were determined by Ingenuity IPA canonical pathway analyses. It was found that
among the most significantly suppressed pathways in
TFEBtg cells includes HIF-1α signaling, IL-10 signaling,
IL-6 signaling, and VEGF signaling pathways (online
supplementary figure S2B). The differences between WT
and TFEBtg MΦs in the expression levels of the genes
shown in figure 1A were also examined. It was shown
that TFEB overexpression significantly ameliorates the
tumor-
promoting gene expression profile in TAM-
like
MΦs (figure 2A). The microarray results were confirmed
by qPCR (figure 2B). These results suggest that TFEB
overexpression may alter the TAM-like MΦ phenotype
by (1) suppressing typical M2 MΦ markers such as Arg1,
IL-10, MMP9, and VEGFA; these molecules are known to
cause immunosuppression and tumor angiogenesis; (2)
increasing the expression of genes involved in autophagy
and lysosome biogenesis, such as LC3, Lamp1, P62, and
ATG5; (3) enhancing PPARγ and inhibiting the NLRP3/
IL-1β/IL-6 inflammatory axis; and (4) suppressing the
PGE2 production axis HIF1α/MIF/cPLA2/COX2. We
examined in our microarray data set if TFEB overexpression affected the expression of genes related antigen
presenting function of MΦs when they are treated with
TCM, such as β2-microglobulin, cathepsin E, and Tap1.
We found no such genes were differentially expressed
in WT or TFEBtg MΦs, suggesting that TFEB expression
levels may not affect MΦs antigen presentation.
Western blot was performed to confirm some of the
gene expression results using WT, TFEBtg and TFEB-/BMDMs. The results show that, in ECM-treated BMDMs,
TFEB overexpression increased the protein levels of
PPARγ and Lamp1 but decreased the phosphorylation
6

of p65 and the protein levels of NLRP3, HIF-1α, MIF,
cPLA2, and Arg1, while TFEB knockout had the opposite
effects on these proteins (figure 2C). We further examined the impact of TFEB overexpression on the production of three direct MΦ effector molecules IL-1β, IL-6 and
PGE2. We treated WT and TFEBtg BMDMs with ECM
for 24 hours, then the cells were rinsed and cultured in
fresh, serum-free DMEM for a further 16 hours before
the medium was collected for ELISA measurement of
IL-1β and IL-6, and colorimetric measurement of PGE2.
The data show that TFEB overexpression significantly
suppressed the elevated levels of IL-1β, IL-6 and PGE2 in
ECM-treated BMDMs (figure 2D).
TFEB directly regulates PPARγ expression in TAMs
TFEB binds to a short consensus sequence CANNTG
called the E-
box on target gene promoters or intron
regions to control gene transcription.29 It has been
reported that TFEB transcriptionally regulates PPARγ
expression in human adipocytes.30 To test if TFEB
directly regulates PPARγ transcription in mouse MΦs,
we performed a promoter assay. As shown in figure 3A,
TFEB overexpression increased luciferase activity in the
cells transfected with E-box containing plasmids PPARγ1158 and PPARγ-891, suggesting that the first and at least
one of 2–4 E-boxes are directly involved in TFEB binding.
To provide further evidence that PPARγ is directly
involved in mediating the effects of TFEB on TAMs, the
PPARγ antagonist GW9662 was used to inhibit its activity in
BMDMs. WT and TFEBtg BMDMs were treated with ECM
with or without 10 µM GW9662 for 24 hours (figure 3B,C
and online supplementary figure S3). Both mRNA and
protein levels of TFEB in BMDMs were not altered by
PPARγ inhibition, and PPARγ inhibition did not change
Beclin 1 protein levels in BMDMs. Interestingly, while
PPARγ mRNA expression was not changed by GW9662,
its protein levels were remarkably reduced by GW9662
in ECM-
treated TFEBtg BMDMs to a level comparable
with ECM-
treated WT BMDMs (both almost undetectable). The mechanism by which GW9662 reduces PPARγ
protein in BMDMs is unknown. Importantly, PPARγ inhibition increased p65 phosphorylation and the expression
of NLRP3, IL-1β, HIF-1α, and cPLA2 in both ECM-treated
WT and TFEBtg BMDMs. The differences between ECM-
treated WT and TFEBtg BMDMs in p65 phosphorylation
and expression of NLRP3 (mRNA and protein), IL-1β
(mRNA), HIF-1α (protein), and cPLA2 (protein) were
diminished, but the differences in HIF-1α and cPLA2
mRNA levels were not decreased. These results suggest
that PPARγ partially mediates the suppressive effects of
TFEB on NF-κB activation and NLRP3 and HIF-1α upregulation in ECM-treated BMDMs. Taken together, these data
demonstrate that TFEB directly regulates PPARγ transcription and partially through this mechanism, TFEB modulates NLRP3/IL-1β and HIF1α/cPLA2 pathways in MΦs.
TFEB’s regulation of MΦs is partially dependent on autophagy
TFEB is a key regulator of autophagy and lysosome
biogenesis,20 and autophagy and associated lysosomal
Li Y, et al. J Immunother Cancer 2020;8:e000543. doi:10.1136/jitc-2020-000543
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Figure 2 Transcriptionfactor EB (TFEB) overexpression alters the gene expression profile in macrophages (MΦs). (A) Bone
marrow–derived macrophages (BMDMs) from wild-type (WT) or MΦ-specific TFEB transgenic (MΦ-TFEBtg) mice were treated
with Dulbecco’s modified Eagle medium (DMEM) or EO771 cell conditioned medium (ECM) for 24 hours; microarray was
performed to analyze their gene expression profiles. A heatmap of genes differentially expressed in WT or TFEBtg is shown
in online supplementary figure S2. A list of key genes that play roles in tumor-associated macrophage (TAM) functions is
shown; relative expression means the ratio of the gene expression levels in TFEBtg MΦs compared with those in WT MΦs.
The microarray data have been deposited in Gene Expression Omnibus (GEO) database (accession number GSE139554). (B)
Quantitativereal-time PCR (qPCR) confirmation of the microarray data for the key genes. n=3, *p<0.05; **p<0.01; ***p<0.001;
two-tailed Student’s t-test. (C) Western blot analysis of indicated proteins in BMDMs from WT, MΦ-TFEBtg or MΦ-TFEB-/- mice.
The cells were treated with ECM for 24 hours. The number under a band indicates the relative intensity of the protein to β-actin
(the relative intensity of the first band is set as 1). A representative blot is shown. (D) BMDMs from WT and TFEBtg MΦs were
treated with DMEM or ECM for 24 hours; then the medium was replaced with fresh DMEM, and the conditioned medium was
collected 16 hours later for analysis for IL-1β, IL-6 and prostaglandin E2 contents. n=5, *p<0.05; two-tailed Student’s t-test.
Arg1, arginase 1; COX2, cyclo-oxygenase-2; cPLA2, cytosolic phospholipases A2; HIF-1α, hypoxia-inducible factor 1α; IL,
interleukin; NLRP3, NLR Family Pyrin Domain Containing 3; PPARγ, peroxisome proliferator-activated receptor γ; TNFα, necrosis
tumor factor α.
Li Y, et al. J Immunother Cancer 2020;8:e000543. doi:10.1136/jitc-2020-000543

7

J Immunother Cancer: first published as 10.1136/jitc-2020-000543 on 2 June 2020. Downloaded from http://jitc.bmj.com/ on August 31, 2022 at Washington University School of Medicine
Library &. Protected by copyright.

Open access

Figure 3 PPARγ mediates part of the effects of TFEB in macrophages (MΦs). (A) Luciferase promoter activity assay of the
binding of TFEB to PPARγ promoter regions; **p<0.01. (B) Western blot analysis of the indicated protein levels in wild-type (WT)
or TFEB transgenic (TFEBtg) bone marrow–derived MΦs (BMDMs) treated with EO771 cell conditioned medium (ECM) with
or without GW9662, a PPARγ antagonist. The quantification is shown in online supplementary figure S3. (C) Quantitative real-
time PCR analysis of expression of the indicated genes in WT and TFEBtg BMDMs treated with ECM with or without GW9662.
n=3; *p<0.05, **p<0.01, ***p<0.001; two-tailed Student’s t-test. Arg1, arginase 1; COX2, cyclo-oxygenase-2; cPLA2, cytosolic
phospholipases A2; HIF-1α, hypoxia-inducible factor 1α; IL, interleukin; PPARγ, peroxisome proliferator-activated receptor γ;
TFEB, transcription factor EB.

activation are known to counteract NLRP3 inflammasome activity15 and mediate HIF-1α degradation.16
PI3K is required for autophagy and its inhibitor LY294002
8

can inhibit autophagic sequestration, a required first
step of autophagy.31 Therefore, we aimed to examine
if autophagy inhibition by LY294002 could negate the
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Figure 4 Autophagy-lysosome axis partially mediates the effects of transcription factor EB (TFEB) in macrophages (MΦs). (A)
Western blot analysis of indicated proteins in wild-type (WT) or TFEB transgenic (TFEBtg) bone marrow–derived MΦs (BMDMs)
treated with EO771 cell conditioned medium (ECM) with or without LY294002, a PI3K and autophagy inhibitor. (B) Band
intensities of selected proteins were quantified by Gel-Pro Analyzer software and normalized by β-actin protein; n=3, *p<0.05,
**p<0.01. The quantification of other proteins is shown in online supplementary figure S4. (C) Quantitativereal-time PCR analysis
of the expression of indicated genes in WT or TFEBtg BMDMs treated with ECM with or without LY294002. Data are presented
as mean±SD; n=3. *p<0.05, **p<0.01, ***p<0.001; two-tailed Student’s t-test. cPLA2, cytosolic phospholipases A2; HIF-1α,
hypoxia-inducible factor 1α; IL, interleukin; NLRP3, NLR Family Pyrin Domain Containing 3; PPARγ, peroxisome proliferator-
activated receptor γ.

impact of TFEB overexpression on MΦs. We treated WT
and TFEBtg BMDMs with ECM with or without LY294002
and measured the expression of some of the key molecules mentioned previously. LY294002 could effectively
block autophagy by abolishing Beclin 1 protein, but
it did not change the expression of TFEB and PPARγ,
nor did it affect p65 phosphorylation in either ECM-
treated WT or TFEBtg BMDMs (figure 4A–C and online
Li Y, et al. J Immunother Cancer 2020;8:e000543. doi:10.1136/jitc-2020-000543

supplementary figure S4). Importantly, autophagy inhibition significantly enhanced NLRP3, IL-1β, HIF-1α, and
cPLA2 expression in both ECM-treated WT and TFEBtg
BMDMs, and diminished the differences in HIF-1α and
cPLA2 protein levels in those cells (figure 4A–C and
online supplementary figure S4). These results suggest
that autophagy partially mediates the beneficial effects
of TFEB on TAMs.
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Trehalose activates MΦ TFEB and suppresses orthotopic
breast tumor growth
Our previous study showed that trehalose, a natural
disaccharide, activates MΦ TFEB and enhances MΦ autophagy and phagocytosis of apoptotic cells.21 We here first
confirmed that similar to HPβCD, also a TFEB activator,32
and chloroquine, an autophagic flux inhibitor that activates TFEB,33 trehalose increased TFEB nuclear translocation and total cellular TFEB in ECM-
treated MΦs
(online supplementary figure S5A,B). To test whether
trehalose can modulate TAM function in breast tumors
through activating TFEB, we treated BMDMs with ECM
with or without trehalose. qPCR showed that while
trehalose did not affect the expression of TFEB in ECM-
treated MΦs, activation of TFEB by trehalose replicated
the gene expression profile observed in TFEBtg MΦs,
including increased expression of PPARγ and Lamp1,
and decreased expression of NLRP3, IL-1β, HIF-1α,
cPLA2 and COX2 (figure 5A). The results were further
confirmed by western blot analysis (figure 5B and online
supplementary figure S5C). Furthermore, trehalose treatment reduced the secretion of IL-1β, IL-6, and PGE2
from ECM-treated MΦs (figure 5C). We then examined
if the activation of TFEB by trehalose is dependent on
autophagy. We treated BMDMs from MΦ-specific Atg5
knockout mice25 and control WT littermates with trehalose, and we found that (1) Atg5 depletion is very efficient in the MΦs from MΦ-specific Atg5 knockout mice,
(2) trehalose significantly increased Atg5 expression in
WT MΦs but not in Atg5-deficient MΦs, and (3) trehalose
equally increased the expression of TFEB targeted gene
PPARγ in WT and Atg5-deficient MΦs (online supplementary figure S5D). These results confirmed that trehalose
activates TFEB in MΦs independent of autophagy since
Atg5 is required for autophagy.
We next tested if trehalose treatment could inhibit
breast tumor growth. We treated female Balb/c mice
with trehalose for 25 days at 2 g/kg, three times per week,
starting 1 day after 4T1 cell inoculation, and monitored
the growth of the tumors. It is shown that trehalose treatment significantly delayed tumor growth (figure 5D).
To verify if the benefit of trehalose in indeed due to
the modulation of the immune microenvironment, we
performed qPCR to measure the expression of Arg1 and
IFNγ to reflect the abundance of M2-like TAMs and cytotoxic T cells, respectively, in the tumors. We found that
the tumors from trehalose treated mice displayed significantly lower expression of Arg1 but higher expression
of IFNγ (online supplementary figure S6A). The experiment was repeated using C57Bl/6 mice inoculated with
EO771 cells; a sucrose control group also was included.
The results show that trehalose, but not sucrose, significantly reduced breast tumor growth (figure 5E). In addition, we used the C3(1)/SV40Tag spontaneous breast
tumor mouse model to confirm the effects of trehalose.
Female C3(1)/SV40Tag mice were treated with trehalose
(2 g/kg, three times a week) or vehicle from 6 to 17 weeks
of age. The results demonstrated a trend in the reduction
10

of mammary gland tumor size related to trehalose administration but not in the number of tumors (online supplementary figure S6B).
TFEB expression is a positive marker for breast cancer
prognosis
We used the TCGA database to analyze the association
between the expression of TFEB or its regulated genes
and breast cancer survival. We found 822 patients with
low TFEB expression and 253 patients with high TFEB
expression. The data indicate that 5-
year survival is
significantly higher in the patients with higher TFEB
expression levels compared with those with lower TFEB
expression levels (87% vs 80%, p=0.0036) (figure 6A).
Similarly, higher expression levels of SOCS3 and PPARγ
are correlated with a higher survival rate, while higher
expression levels of HIF-1α are associated with a lower
survival rate (figure 6A). The result was confirmed
using another online analysis platform. TFEB, SOCS3,
and PPARγ are shown to be positive prognostic factors,
while HIF-1α is a negative prognostic factor (figure 6B).
Although the expression of these genes is not only from
TAMs, the data suggest that activating TFEB and thus
increasing the expression of SOCS3 and PPARγ while
reducing the expression of HIF-1α in breast tumors may
be beneficial for patients with breast cancer. To further
examine if suppression of TFEB expression in TAMs is
true in human breast tumors, we stained TFEB using
human breast tumor specimens. Breast tumors from five
triple negative breast cancer patients were stained for
CD68, TFEB and 4′,6-diamidino-2-phenylindole (DAPI).
The data show that TFEB staining intensity is significantly
lower in the MΦs in the tumor nest than that in the tumor
periphery (online supplementary figure S7).

Discussion
As high as 50% of the cells within breast tumors are MΦs,
called TAMs; and these TAMs play important roles in
tumor development, metastasis, and resistance to therapies including recently developed immune check point
inhibitors.34 Therefore, targeting TAMs is an actively
pursued strategy for solid tumor treatment. MΦ depletion
is not a viable approach since these cells are the first line
of defense against infection and play vital roles in many
physiological processes. Blocking the tumor-promoting
signaling pathways and antagonizing resulting key effector
molecules in TAMs are promising approaches. However,
there are many interconnected pathways that collectively
define the phenotype of TAMs and numerous effector
molecules that execute tumor-promoting functions, thus
targeting any single pathway or effector molecule is not
sufficient to achieve clinical benefit.
We identified TFEB as a target whose activation results
in beneficial alterations in several key pathways and
suppression of many tumor-promoting effector molecules
in TAMs (figure 6C). First, TFEB upregulates SOCS3
and thus suppresses STAT3 activation, thereby blocking
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Figure 5 TFEB activator trehalose modulates macrophages (MΦs) function and suppresses breast tumor growth. (A)
Quantitative real-time PCR analysis of expression of the indicated genes in mouse peritoneal MΦs (pMΦs) treated EO771 cell
conditioned medium (ECM) with or without trehalose. (B) Western blot analysis of indicated proteins in mouse pMΦs treated
with ECM with or without trehalose. The quantification is shown in online supplementary figure S5C. (C) IL-1β, IL-6 and PGE2
productions were determined in medium of mouse pMΦs treated with ECM with or without trehalose. n=4, *p<0.05, **p<0.01.
(D) Growth curve of orthotopic 4T1 breast tumors in female Balb/c mice treated with vehicle or trehalose. Data are expressed
as mean±SD for each group; Student’s t-test; *p<0.05, vs Veh (vehicle). (E) EO771 breast tumor-bearing mice were treated with
Veh, trehalose or sucrose for 20 days before the mice were sacrificed for tumor measurement. One-way analysis of variance
with Bonferroni’s post-test; *p<0.05. COX2, cyclo-oxygenase-2; cPLA2, cytosolic phospholipases A2; HIF-1α, hypoxia-inducible
factor 1α; IL, interleukin; MΦs, macrophages; NLRP3, NLR Family Pyrin Domain Containing 3; PBS, phosphate-buffered saline;
PGE, prostaglandin E2; PPARγ, peroxisome proliferator-activated receptor γ; TFEB, transcription factor EB.
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Figure 6 The clinical relevance of macrophage (MΦ) signaling axes regulated by transcription factor EB (TFEB). (A) The
prognostic value of TFEB and the genes regulated by TFEB for patients with breast cancer based on the CTGA Human Protein
Atlas database. (B) The prognostic value of TFEB and the genes regulated by TFEB for patients with breast cancer based on
the online survival analysis platform www.kmplot.com. (C) A schematic drawing depicting how TFEB regulates macrophage
functions in breast tumors. Arg1, arginase 1; COX2, cyclo-oxygenase-2; cPLA2, cytosolic phospholipases A2; HIF-1α, hypoxia-
inducible factor 1α; IL, interleukin; NLRP3, NLR Family Pyrin Domain Containing 3; PGE, prostaglandin E2; PPARγ, peroxisome
proliferator-activated receptor γ; SOCS3, suppressor of cytokine signaling 3.
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MΦ M2-
like polarization and the production of Arg1
and IL-10.23 Second, TFEB activates the transcription of
PPARγ, which blunts NFκB activation, resulting in downregulation of NLRP3/IL-1β/IL-6 axis and HIF-1α transcription. Third, TFEB enhances autophagy and lysosome
activities, which counteract the NLRP3 inflammasome as
well as lead to degradation of HIF-1α protein.
PPARγ is at the critical crossroad of inflammation and
lipid metabolism. In TAMs, NFκB is activated through
multiple pathways, including TLR activation35 and
response to hypoxia,36 leading to transcription of proinflammatory cytokines and HIF-1α.37 PPARγ acts as an
E3 ligase that induces the degradation of NFκB/p65.37
Our data demonstrate that TFEB upregulates PPARγ by
directly binding to its promoter, and thereby downregulates inflammatory mediators NLRP3, IL-1β and IL6, and
HIF-1α.
During MΦ inflammatory responses, NLRP3 and IL-1β
expression is controlled by NF-κB (nuclear factor kappa-
light-
chain-
enhancer of activated B cells), and NLRP3
inflammasome processes pro-IL-1β protein into mature
IL-1β.38 In breast cancer, IL-1β has been linked to the
proliferation, invasion, angiogenesis, and inhibition of
apoptosis in cancer cells.39 IL-1β further induces IL-6
expression40; and IL-6 not only induces cancer cell proliferation, but also induces EMT and the formation and
maintenance of breast cancer stem cells.41 The NLRP3
inflammasome is known to be negatively regulated by
autophagy/lysosome.15 Our data show that in TAMs,
TFEB may negatively regulate NLRP3 inflammasome via
PPARγ-mediated NFκB suppression and enhanced autophagy and lysosome activities.
In response to the hypoxic TME, the expression of
HIF-1α is upregulated and the protein is stabilized in
cancer cells as well as stromal cells including TAMs.
Among several downstream signaling events, HIF-1α
in MΦs activates the MIF/cPLA2/COX2 axis, leading
to PGE2 production.13 PGE2 promotes breast cancer
progression by multiple mechanisms: inactivation of host
antitumor immune cells,42 43 stimulation of tumor cell
migration and invasiveness,44–46 induction of stem-
like
47
44
cells, tumor-
associated angiogenesis and lymphangiogenesis.48 Our results suggest that in breast tumors,
TFEB suppresses HIF-1α transcription via PPARγ-mediated NFκB inactivation and also reduces HIF-1α protein
by autophagy/lysosome-mediated degradation in TAMs,
leading to suppression of the MIF/cPLA2/COX2
signaling pathway and reduced production of PGE2.
These cell culture study results are further strengthened by mouse studies showing that (1) MΦ-specific
TFEB knockout promoted breast tumor growth by
enhancing the tumor-
promoting phenotype of TAMs;
and (2) trehalose, a TFEB activator, modulated MΦ gene
expression and function towards a less tumor-promoting
phenotype and thereby inhibited breast tumor growth in
multiple breast cancer mouse models. Moreover, analysis
of breast cancer patient tumor genome data revealed
Li Y, et al. J Immunother Cancer 2020;8:e000543. doi:10.1136/jitc-2020-000543

that TFEB, SOCS3, and PPARγ are positive prognostic
markers of breast cancer, while HIF-1α is a negative prognostic marker. While TAMs only contribute to part of the
expression levels of these genes, the human data suggest
that therapies that increase the expression or activity of
TFEB in TAMs as well as other cell types in breast tumors
may be effective in halting breast cancer development.

Conclusions
Our study identifies TFEB as a master regulator of TAMs
in breast cancer. TFEB controls TAM gene expression and
function through multiple pathways. By activating SOCS3,
TFEB suppresses STAT3 signaling for M2-like activation
of MΦs. By upregulating PPARγ, TFEB suppresses NF-κB
activation and thus inflammasome activity and HIF-1α
mediated hypoxic response. By activating autophagy/lysosome activities, TFEB promotes degradation of NLRP3
inflammasomes and HIF-1α protein. Collectively, TFEB
activation simultaneously inhibits multiple effector molecules that exert the tumor-promoting function of TAMs,
including Arg1, IL-10, IL-1β, IL-6 and PGE2. Therefore,
TFEB is a promising therapeutic target for breast cancer
and possibly other solid malignant tumors.
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